[68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases.
CCRT = concurrent chemoradiation therapy
CT = computed tomography
ENB = esthesioneuroblastoma
FDG = fluorodeoxyglucose
LAR = long-acting release
MIP = maximum intensity projection
MRI = magnetic resonance imaging
NET = neuroendocrine tumor
PET
PET = positron emission tomography
PRRT
PRRT = peptide receptor radionuclide therapy
RT = radiotherapy
SSTR = somatostatin receptor
SUV = standardized uptake value
[177Lu]-DOTATATE
[68Ga]-DOTATATE
esthesioneuroblastoma
olfactory neuroblastoma
Journal
Journal of neurosurgery. Case lessons
ISSN: 2694-1902
Titre abrégé: J Neurosurg Case Lessons
Pays: United States
ID NLM: 9918227275606676
Informations de publication
Date de publication:
11 Jan 2021
11 Jan 2021
Historique:
received:
01
11
2020
accepted:
06
11
2020
entrez:
20
7
2022
pubmed:
11
1
2021
medline:
11
1
2021
Statut:
epublish
Résumé
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare sinonasal neuroectodermal malignancy with a slow onset of symptoms, favorable 5-year survival, and a propensity for delayed locoregional recurrence. Current treatment options include resection, adjuvant radiotherapy, and/or chemotherapy; however, because of its rarity and location, determining the optimal treatment for ENB has been challenging. ENBs strongly express somatostatin receptors (SSTRs), particularly SSTR2, providing a molecular target for imaging and therapy. The authors present a case series of ENBs imaged with [68Ga]-DOTATATE PET/MRI and PET/CT and discuss the emerging role of [68Ga]-DOTATATE PET for ENB diagnosis, staging, and treatment response monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare sinonasal neuroectodermal malignancy with a slow onset of symptoms, favorable 5-year survival, and a propensity for delayed locoregional recurrence. Current treatment options include resection, adjuvant radiotherapy, and/or chemotherapy; however, because of its rarity and location, determining the optimal treatment for ENB has been challenging.
OBSERVATIONS
METHODS
ENBs strongly express somatostatin receptors (SSTRs), particularly SSTR2, providing a molecular target for imaging and therapy.
LESSONs
UNASSIGNED
The authors present a case series of ENBs imaged with [68Ga]-DOTATATE PET/MRI and PET/CT and discuss the emerging role of [68Ga]-DOTATATE PET for ENB diagnosis, staging, and treatment response monitoring.
Identifiants
pubmed: 35854930
doi: 10.3171/CASE2058
pii: CASE2058
pmc: PMC9241319
doi:
Types de publication
Case Reports
Langues
eng
Pagination
CASE2058Informations de copyright
© 2021 The authors.
Déclaration de conflit d'intérêts
Disclosures Dr. Ivanidze received grants from Advanced Accelerator Applications, A Novartis Company, for this work and receives grants from GE Healthcare for activities outside of this work. Dr. Lin received grants from Novartis for this work. Dr. Roytman reports a 2019 RSNA Resident Research Grant (RR#1962).
Références
J Neurol Surg B Skull Base. 2016 Feb;77(1):1-5
pubmed: 26949582
J Clin Oncol. 2018 Sep 1;36(25):2578-2584
pubmed: 29878866
Nucl Med Commun. 2010 Dec;31(12):1025-32
pubmed: 20926978
Yonsei Med J. 2020 Mar;61(3):257-261
pubmed: 32102127
Curr Oncol Rep. 2018 Feb 7;20(1):7
pubmed: 29411144
J Nucl Med. 2020 Sep;61(9):1326-1330
pubmed: 32005769
Head Neck Pathol. 2015 Mar;9(1):51-9
pubmed: 24806334
Head Neck Pathol. 2009 Sep;3(3):252-9
pubmed: 20596981
Exp Ther Med. 2016 Nov;12(5):3078-3082
pubmed: 27882120
Lancet Oncol. 2001 Nov;2(11):683-90
pubmed: 11902539
Head Neck. 2006 Apr;28(4):305-12
pubmed: 16470879
Radiographics. 2015 Mar-Apr;35(2):500-16
pubmed: 25763733
Skull Base. 2009 Mar;19(2):133-40
pubmed: 19721769
Clin Imaging. 2019 Jul - Aug;56:146-154
pubmed: 31121520
J Surg Oncol. 2019 Jan;119(1):130-142
pubmed: 30466166
Laryngoscope. 2016 Jul;126(7):1556-61
pubmed: 26865537
Oper Neurosurg (Hagerstown). 2018 Dec 1;15(6):100-109
pubmed: 29554305
Cancer. 1976 Mar;37(3):1571-6
pubmed: 1260676
Head Neck Pathol. 2018 Mar;12(1):22-30
pubmed: 29427030